Cancer Stem Cells

Cancer is a devastating disease that affects millions of people in the world. Our the- pies for tumors have mostly been based on classical chemotherapy and antiproliferative treatments. More recently, directed therapies against a causative oncogene have led to prominent reduction in tumor rates for some cancers. For instance, chronic myelogenous leukemia that is due to a BCR–ABL translocation can be targeted with Gleevec. Despite these advances in individual tumors, a number of patients are treated for their primary tumors and ultimately relapse. Relapsing tumors can be due to resistance to chemotherapy or to antioncogene drugs. Another hypothesis is that heterogeneity in the tumor leads to an inability of classical chemotherapy to completely eradicate all cells of the tumor. This concept of heterogeneity has led some investigators to propose a cancer stem cell model. As patients are treated with chemotherapy, most of the dividing cells are killed, but this leaves a small subset of cells that have the ability to remake the entire tumor. These are cancer stem cells. They possess the signals of self-renewal and yet can also differentiate. If one could understand more about the cells that remain after classical chemotherapy or the cells that can remake the tumor among the heterogeneous population, this information would have a huge impact on our treatment of cancer.

“From the reviews:This volume in the popular Methods in Molecular Biology series provides a state-of-the art compendium of research techniques and protocols for identifying and culturing rare populations of cancer stem cells. … The audience includes basic science and clinical researchers who are interested in stem cell biology as well as mechanisms of carcinogenesis and malignancy. The book also will be valued by biomedical scientists and clinicians interested in clinical oncology. … The topic is fascinating and clinically relevant. (Bruce A. Fenderson, Doody's Review Service, June, 2010)”

From the reviews:

“This volume in the popular Methods in Molecular Biology series provides a state-of-the art compendium of research techniques and protocols for identifying and culturing rare populations of cancer stem cells. … The audience includes basic science and clinical researchers who are interested in stem cell biology as well as mechanisms of carcinogenesis and malignancy. The book also will be valued by biomedical scientists and clinicians interested in clinical oncology. … The topic is fascinating and clinically relevant.” (Bruce A. Fenderson, Doody’s Review Service, June, 2010)

Through the revolutionary concept of cancer stem cells, cancer research has been reinvigorated to study the role of these unique cells in cancer propagation and as targets of innovative therapies. In Cancer Stem Cells: Methods and Protocols, preeminent researchers have compiled cancer stem cell research techniques and protocols to promote healthy competition, discourse, and collaboration in this vital field. The volume covers extensive topics such as identification and isolation of cancer stem cells, animal models of cancer stem cells, methylation profiling, the contribution of the niche in the regulation of cancer stem cells, immunologic targeting, and the use of normal stem cells as a treatment, among other subjects. Written in the highly successful Methods in Molecular Biology(tm) series format, chapters include brief introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and expert notes on troubleshooting and avoiding known pitfalls. Comprehensive and cutting-edge, Cancer Stem Cells: Methods and Protocols will aid scientists around the world in the furthering of our understanding of cancer initiation and propagation and, most importantly, in the development of novel targets for cancer therapy.

Cancer is a devastating disease that affects millions of people in the world. Our the- pies for tumors have mostly been based on classical chemotherapy and antiproliferative treatments. More recently, directed therapies against a causative oncogene have led to prominent reduction in tumor rates for some cancers. For instance, chronic myelogenous leukemia that is due to a BCR-ABL translocation can be targeted with Gleevec. Despite these advances in individual tumors, a number of patients are treated for their primary tumors and ultimately relapse. Relapsing tumors can be due to resistance to chemotherapy or to antioncogene drugs. Another hypothesis is that heterogeneity in the tumor leads to an inability of classical chemotherapy to completely eradicate all cells of the tumor. This concept of heterogeneity has led some investigators to propose a cancer stem cell model. As patients are treated with chemotherapy, most of the dividing cells are killed, but this leaves a small subset of cells that have the ability to remake the entire tumor. These are cancer stem cells. They possess the signals of self-renewal and yet can also differentiate. If one could understand more about the cells that remain after classical chemotherapy or the cells that can remake the tumor among the heterogeneous population, this information would have a huge impact on our treatment of cancer.

This item is eligible for free returns within 30 days of delivery. See our returns policy for further details.